Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Susan E. Barrowcliffe sold 18,390 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $22.00, for a total transaction of $404,580.00. Following the completion of the sale, the insider now owns 3,223 shares in the company, valued at approximately $70,906. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) traded up 5.11% during trading on Thursday, hitting $22.83. 394,070 shares of the stock were exchanged. The firm’s market capitalization is $1.15 billion. Aimmune Therapeutics, Inc. has a 52 week low of $14.11 and a 52 week high of $27.31. The stock’s 50 day moving average price is $20.61 and its 200 day moving average price is $20.17.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.01. On average, equities analysts predict that Aimmune Therapeutics, Inc. will post ($2.71) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Aimmune Therapeutics, Inc. (AIMT) Insider Sells $404,580.00 in Stock” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/07/aimmune-therapeutics-inc-aimt-insider-sells-404580-00-in-stock.html.

A number of institutional investors and hedge funds have recently made changes to their positions in AIMT. SG Americas Securities LLC boosted its position in Aimmune Therapeutics by 10.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 499 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Aimmune Therapeutics by 454.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 4,900 shares during the period. Legal & General Group Plc boosted its position in Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 1,634 shares during the period. Voya Investment Management LLC lifted its position in shares of Aimmune Therapeutics by 31.2% in the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 3,757 shares during the period. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Aimmune Therapeutics in the 2nd quarter worth about $333,000. 72.90% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have weighed in on AIMT. Wedbush restated an “ourperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a research report on Monday, August 14th. BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. ValuEngine upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Finally, Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Aimmune Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $32.50.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.